Compare ICMB & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | COCP |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.1M |
| IPO Year | 2013 | 2011 |
| Metric | ICMB | COCP |
|---|---|---|
| Price | $0.78 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 85.2K | 24.9K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.86 |
| 52 Week High | $3.12 | $2.19 |
| Indicator | ICMB | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 35.76 |
| Support Level | $0.73 | $0.91 |
| Resistance Level | $1.29 | $1.09 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 31.60 | 12.38 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.